查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1890923

坏死性筋膜炎市场按类型、治疗方法、给药途径、解剖部位、最终用户、通路、风险因素、年龄层和地区划分

Necrotizing Fasciitis Market, By Type, By Treatment Modality, By Route of Administration, By Anatomical Location, By End User, By Distribution Channel, By Risk-Factor, By Age Group, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3个工作天内

价格
简介目录

坏死性筋膜炎市场预计在 2025 年达到 12.1 亿美元，预计到 2032 年将达到 21.4 亿美元，2025 年至 2032 年的复合年增长率为 8.5%。

报告内容 报告详情
基准年： 2024 2025年市场规模： 12.1亿美元
历史数据时期： 2020年至2024年 预测期： 2025年至2032年
预测期（2025-2032年）复合年增长率： 8.50% 2032 年的预测值： 21.4亿美元

坏死性筋膜炎是最严重、进展最快的软组织感染疾病之一，其特征是筋膜和周围组织大面积坏死，需要立即进行医疗干预以防止致命后果。

这种罕见但严重的细菌感染疾病，常被称为“食肉病”，会影响皮肤深层和皮下组织。即使采取积极的治疗通讯协定，死亡率也高达20%至40%。全球坏死性筋膜炎市场涵盖了诊断工具、治疗性介入、手术器械和辅助护理技术等一系列旨在对抗这种危及生命的疾病的综合生态系统。

市场成长的驱动因素包括医疗专业人员意识的提高、快速诊断技术的进步以及标靶抗菌疗法的开发。主要市场细分包括诊断解决方案（如影像技术和检测套组）、治疗产品（如频谱抗生素和免疫球蛋白疗法）以及伤口清创手术所需的外科器械。

此外，糖尿病和免疫力缺乏疾病的日益普遍增加了严重软组织感染疾病的风险，开发中国家医疗保健支出不断增加，以及持续开展的旨在改善患者预后和缩短治疗时间的研究工作，也都在影响着市场格局。

市场动态

全球坏死性筋膜炎市场主要受几个强有力的因素驱动，这些因素共同推动市场扩张和创新：全球糖尿病和其他免疫力缺乏疾病的发病率不断上升，显着增加了严重软组织感染疾病的风险，并扩大了需要特殊治疗性介入的患者群体。

医疗保健意识的提高和诊断能力的提升使得早期发现和早期疗育成为可能，这对患者的生存和康復结果具有决定性影响。快速诊断工具的技术进步，包括就地检验设备和先进成像设备，促进了坏死性筋膜炎的早期识别，从而推动了市场对创新诊断解决方案的需求。

此外，新型抗菌药物和联合治疗的研发正在应对日益严重的抗生素抗药性问题，而新兴经济体医疗保健支出的成长也有助于扩大市场准入。然而，该市场面临着许多限制因素，包括疾病的罕见性限制了大规模临床试验的开展，延缓了研究进展；以及与紧急治疗通讯协定和长期住院相关的高昂费用，给患者和医疗保健系统都带来了经济负担。

诊断的复杂性往往会导致治疗启动延迟，从而造成患者预后不良，并为医疗机构带来诉讼风险。此外，基层医疗医师和急诊室工作人员缺乏相关意识也会导致误诊和延误识别。儘管存在这些挑战，但在开发快速诊断平台、创建标靶治疗方案、扩展远端照护能力以进行远距会诊和诊断以及建立专科治疗中心等领域仍存在着巨大的机会。

本次调查的主要特点

  • 本报告对全球坏死性筋膜炎市场进行了详细分析，以 2024 年为基准年，给出了预测期（2025-2032 年）内的市场规模（十亿美元）和復合年增长率（%）。
  • 该报告还重点介绍了各个细分市场的潜在商机，并概述了该市场具有吸引力的投资提案矩阵。
  • 该研究还提供了有关市场驱动因素、阻碍因素、机会、新产品发布或核准、市场趋势、区域展望以及主要参与者采取的竞争策略的重要见解。
  • 本报告根据以下参数介绍了全球坏死性筋膜炎市场主要企业的概况：公司概况、产品系列、主要亮点、财务表现和策略。
  • 本报告的研究结果将使负责人和企业经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
  • 这份全球坏死性筋膜炎市场报告的目标受众是该行业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
  • 相关人员可以透过用于分析全球坏死性筋膜炎市场的各种策略矩阵轻鬆做出决策。

目录

第一章 研究目标与前提条件

  • 调查目的
  • 先决条件
  • 简称

第二章 市场范围

  • 报告概述
    • 市场定义和范围
  • 执行摘要

第三章 市场动态、监管与趋势分析

  • 市场动态
  • 司机
  • 抑制因素
  • 机会
  • 影响分析
  • 重大进展
  • 法规环境
  • 产品上市及核准
  • PEST分析
  • 波特分析
  • 併购趋势
  • 产业趋势

4. 2020-2032年全球坏死性筋膜炎市场（按类型划分）

  • 多重微生物（I 型）
  • 单微生物（II 型）
  • 梭菌性/气性坏疽（III型）
  • 其他（例如，真菌性行为感染、非典型病原体）

5. 2020-2032年全球坏死性筋膜炎市场（依治疗方法）

  • 外科/介入治疗（如切除术、切除手术）
  • 抗生素/抗菌疗法
  • 辅助性治疗（例如，高压氧气疗法、创伤护理设备）
  • 其他（辅助治疗）

6. 2020-2032年全球坏死性筋膜炎市场（依给药途径划分）

  • 肠外
  • 口服

7. 2020-2032年全球坏死性筋膜炎市场（依解剖部位划分）

  • 上肢
  • 下肢
  • 会阴部和生殖器（福尼尔坏疽）
  • 头部和颈部
  • 身体躯干和腹壁

8. 2020-2032年全球坏死性筋膜炎市场（依最终用户划分）

  • 医院和诊所
  • 门诊手术中心
  • 復健中心
  • 诊断中心
  • 学术和研究机构
  • 家庭医疗保健

9. 2020-2032年全球坏死性筋膜炎市场依通路划分

  • 医院药房
  • 零售药房
  • 网路药局/网路药局

第十章 全球坏死性筋膜炎市场风险因子分析（2020-2032年）

  • 糖尿病
  • 肥胖
  • 免疫力缺乏/肿瘤患者
  • 週边血管疾病/慢性肾臟病
  • 静脉注射毒品者/酒精成瘾

第十一章 2020-2032年全球坏死性筋膜炎市场（依年龄层划分）

  • 婴儿和儿童（18 岁以下）
  • 成年人（18-64岁）
  • 老年人（65岁以上）

第十二章 2020-2032年全球坏死性筋膜炎市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他拉丁美洲国家
  • 欧洲
    • 德国
    • 英国
    • 西班牙
    • 法国
    • 义大利
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
    • ASEAN
    • 亚太其他地区
  • 中东
    • 海湾合作委员会国家
    • 以色列
    • 其他中东国家
  • 非洲
    • 南非
    • 北非
    • 中非

第十三章 竞争格局

  • Pfizer Inc
  • Merck and Co Inc
  • GlaxoSmithKline plc
  • Novartis AG
  • Bayer AG
  • Abbott Laboratories
  • Baxter International Inc
  • Melinta Therapeutics LLC
  • Atox Bio Inc
  • Wound Care Technologies Inc
  • ConvaTec Group Plc
  • Smith and Nephew plc
  • Molnlycke Health Care AB
  • 3M Company
  • Becton Dickinson and Company

第十四章 分析师建议

  • 机会
  • 分析师观点
  • Coherent Opportunity Map

第十五章 参考文献与调查方法

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI8934

Necrotizing Fasciitis Market is estimated to be valued at USD 1.21 Bn in 2025 and is expected to reach USD 2.14 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.5% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 1.21 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 8.50% 2032 Value Projection: USD 2.14 Bn

Necrotizing fasciitis represents one of the most critical and rapidly progressive soft tissue infections, characterized by extensive necrosis of the fascia and surrounding tissues, demanding immediate medical intervention to prevent fatal outcomes.

This rare but severe bacterial infection, often termed as flesh-eating disease, affects the deep layers of skin and subcutaneous tissues, with mortality rates ranging from 20% to 40% despite aggressive treatment protocols. The global necrotizing fasciitis market encompasses a comprehensive ecosystem of diagnostic tools, therapeutic interventions, surgical instruments, and supportive care technologies designed to combat this life-threatening condition.

The market's evolution is driven by increasing awareness among healthcare professionals, advancements in rapid diagnostic techniques, and the development of targeted antimicrobial therapies. Key market segments include diagnostic solutions such as imaging technologies and laboratory testing kits, therapeutic products including broad-spectrum antibiotics and immunoglobulin treatments, and surgical instruments essential for debridement procedures.

The market landscape is further influenced by the growing prevalence of diabetes and immunocompromised conditions that predispose patients to severe soft tissue infections, alongside rising healthcare expenditure in developing economies and continuous research initiatives focused on improving patient outcomes and reducing treatment timelines.

Market Dynamics

The global necrotizing fasciitis market is primarily driven by several compelling factors that collectively fuel market expansion and innovation. The increasing incidence of diabetes mellitus and other immunocompromising conditions worldwide significantly elevates the risk of severe soft tissue infections, creating a larger patient population requiring specialized treatment interventions.

Rising healthcare awareness and improved diagnostic capabilities enable earlier detection and intervention, which is crucial for patient survival and recovery outcomes. Technological advancements in rapid diagnostic tools, including point-of-care testing devices and advanced imaging modalities, facilitate quicker identification of necrotizing fasciitis, thereby driving market demand for innovative diagnostic solutions.

Additionally, the development of novel antimicrobial agents and combination therapies addresses the growing concern of antibiotic resistance, while increased healthcare spending in emerging economies expands market accessibility. However, the market faces significant restraints including the rarity of the condition, which limits large-scale clinical trials and slows research progress, alongside the high costs associated with emergency treatment protocols and extended hospital stays that create financial barriers for patients and healthcare systems.

The complexity of diagnosis often leads to delayed treatment initiation, resulting in poor patient outcomes and potential litigation concerns for healthcare providers. Furthermore, limited awareness among primary care physicians and emergency department staff can contribute to misdiagnosis or delayed recognition. Despite these challenges, substantial opportunities exist in developing rapid diagnostic platforms, creating targeted therapeutic solutions, expanding telemedicine capabilities for remote consultation and diagnosis, and establishing specialized treatment centers.

Key Features of the Study

  • This report provides in-depth analysis of the global necrotizing fasciitis market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global necrotizing fasciitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Pfizer Inc, Merck and Co Inc, GlaxoSmithKline plc, Novartis AG, Bayer AG, Abbott Laboratories, Baxter International Inc, Melinta Therapeutics LLC, Atox Bio Inc, Wound Care Technologies Inc, ConvaTec Group Plc, Smith and Nephew plc, Molnlycke Health Care AB, 3M Company, and Becton Dickinson and Company
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global necrotizing fasciitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global necrotizing fasciitis market

Market Segmentation

  • Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Polymicrobial (Type I)
    • Monomicrobial (Type II)
    • Clostridial / Gas gangrene (Type III)
    • Others (e.g., Fungal necrotizing infections, atypical pathogens)
  • Treatment Modality Insights (Revenue, USD Bn, 2020 - 2032)
    • Surgical/interventional (e.g., debridement, amputation)
    • Antibiotic/antimicrobial therapy
    • Adjunctive therapies (e.g., hyperbaric oxygen, wound-care devices)
    • Other (Supportive care)
  • Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
    • Parenteral
    • Oral
  • Anatomical Location Insights (Revenue, USD Bn, 2020 - 2032)
    • Upper Extremities
    • Lower Extremities
    • Perineal and Genital (Fournier's Gangrene)
    • Head and Neck
    • Torso and Abdominal Wall
  • End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospitals and Clinics
    • Ambulatory Surgical Centers
    • Rehabilitation Centers
    • Diagnostic Centers
    • Academic and Research Institutes
    • Home Healthcare
  • Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospital pharmacies
    • Retail pharmacies
    • Online/epharmacy
  • Risk-factor Insights (Revenue, USD Bn, 2020 - 2032)
    • Diabetes mellitus
    • Obesity
    • Immunocompromised/oncology patients
    • Peripheral vascular disease/chronic kidney disease
    • Intravenous drug users/alcoholism
  • Age Group Insights (Revenue, USD Bn, 2020 - 2032)
    • Infants and children (< 18 years)
    • Adults (18-64 years)
    • Seniors (65+ years)
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Pfizer Inc
    • Merck and Co Inc
    • GlaxoSmithKline plc
    • Novartis AG
    • Bayer AG
    • Abbott Laboratories
    • Baxter International Inc
    • Melinta Therapeutics LLC
    • Atox Bio Inc
    • Wound Care Technologies Inc
    • ConvaTec Group Plc
    • Smith and Nephew plc
    • Molnlycke Health Care AB
    • 3M Company
    • Becton Dickinson and Company

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Necrotizing Fasciitis Market, By Type
    • Global Necrotizing Fasciitis Market, By Treatment Modality
    • Global Necrotizing Fasciitis Market, By Route of Administration
    • Global Necrotizing Fasciitis Market, By Anatomical Location
    • Global Necrotizing Fasciitis Market, By End User
    • Global Necrotizing Fasciitis Market, By Distribution Channel
    • Global Necrotizing Fasciitis Market, By Risk-Factor
    • Global Necrotizing Fasciitis Market, By Age Group
    • Global Necrotizing Fasciitis Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Necrotizing Fasciitis Market, By Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Polymicrobial (Type I)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Monomicrobial (Type II)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Clostridial / Gas gangrene (Type III)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others (e.g., Fungal necrotizing infections, atypical pathogens)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Necrotizing Fasciitis Market, By Treatment Modality, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Surgical/interventional (e.g., debridement, amputation)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Antibiotic/antimicrobial therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Adjunctive therapies (e.g., hyperbaric oxygen, wound-care devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Other (Supportive care)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Necrotizing Fasciitis Market, By Route of Administration, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Necrotizing Fasciitis Market, By Anatomical Location, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Upper Extremities
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Lower Extremities
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Perineal and Genital (Fournier's Gangrene)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Head and Neck
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Torso and Abdominal Wall
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Necrotizing Fasciitis Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals and Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Rehabilitation Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Diagnostic Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Academic and Research Institutes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Home Healthcare
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Necrotizing Fasciitis Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online/epharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Necrotizing Fasciitis Market, By Risk-Factor, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Diabetes mellitus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Obesity
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Immunocompromised/oncology patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Peripheral vascular disease/chronic kidney disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Intravenous drug users/alcoholism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Necrotizing Fasciitis Market, By Age Group, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Infants and children (< 18 years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Adults (18-64 years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Seniors (65+ years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global Necrotizing Fasciitis Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

13. Competitive Landscape

  • Pfizer Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck and Co Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Abbott Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Baxter International Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Melinta Therapeutics LLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Atox Bio Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Wound Care Technologies Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • ConvaTec Group Plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Smith and Nephew plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Molnlycke Health Care AB
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • 3M Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Becton Dickinson and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

14. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

15. References and Research Methodology

  • References
  • Research Methodology
  • About us